Shots:       Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency        Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients        Samsung Bioepis Collaborates with Harrow to Commercialize its Ophthalmology Biosimilars in the…